WARSAW, Ind., Oct. 25, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Mobi-C® Cervical Disc Prosthesis is now the most widely covered device for one- and two-level cervical disc replacement by commercial health insurers in the United States. Mobi-C, acquired as part of Zimmer Biomet's combination with LDR Holding Corporation in July, is now accessible to more than 200 million insured patients with one-level disc disease and more than 150 million patients with two-level disc disease across more than 90 commercial insurance plans. Zimmer Biomet achieved this significant milestone when Anthem (formerly WellPoint), which reports nearly 40 million enrollees in its health plans, added Mobi-C to the list of covered devices for one-level disc replacement and as the sole cervical total disc prosthesis covered for two-level surgery.
"The widespread coverage of Mobi-C is a testament to payers accepting the peer-reviewed clinical data and real-world evidence from 40,000 procedures, as validation for the significant advantages Mobi-C offers over invasive spinal fusion for patients in need of cervical disc replacement," said Adam Johnson, Group President, Spine, Dental, CMF and Thoracic. "As the most widely insured cervical intervertebral disc prosthesis, Mobi-C is poised to become the standard of care for total cervical disc replacement, which is welcome news for the millions of patients who are looking for a safe and effective option for the treatment of one level or two contiguous levels in the cervical spine."
Mobi-C was the first cervical disc prosthesis approved by the U.S. Food and Drug Administration for reconstruction of the cervical disc at both one and two levels to treat arm pain and/or neurological deficit caused by various spine disorders or injuries. Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling to accommodate vertebral anchorage such as screws or keels. Unlike cervical fusion, the current standard of care, which immobilizes the targeted vertebrae, Mobi-C features patented mobile-bearing technology designed to allow the prosthetic disc to self-adjust to facilitate motion similar to that of the natural cervical spine. To learn more about Mobi-C, visit www.cervicaldisc.com.
"Expanding payer coverage for the Mobi-C Cervical Disc prosthesis has been a critically important priority and solidifies Zimmer Biomet's foothold as a market leader in cervical disc replacement," said David Dvorak, President and CEO of Zimmer Biomet. "The Mobi-C Cervical Disc, coupled with our differentiated and comprehensive Spine portfolio of innovative surgical solutions, strengthens Zimmer Biomet's position for sustainable growth."
At the annual meeting of the North American Spine Society (NASS) this week, the Company plans to present data from a seven-year study confirming the statistical superiority of two-level cervical disc arthroplasty with Mobi-C over two-level anterior cervical discectomy and fusion (ACDF).
For more information about Zimmer Biomet and its musculoskeletal health offerings, please visit the Company online at www.zimmerbiomet.com.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
SOURCE Zimmer Biomet Holdings, Inc.